Evidence map›Paper›PMID 34254179›Full record

Observational studyClinical research in cardiology : official journal of the German Cardiac Society2021

Prognostic value of hepatorenal function following transcatheter edge-to-edge mitral valve repair.

Tetsu Tanaka, Refik Kavsur, Maximilian Spieker, Christos Iliadis, Clemens Metze, Patrick Horn, Atsushi Sugiura, Stephan Baldus, Malte Kelm, Georg Nickenig and 3 more

Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Clinical research in cardiology : official journal of the German Cardiac Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Tetsu Tanaka *Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Refik Kavsur *Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Maximilian Spieker *Department of Cardiology, Heart Center, University Hospital Düsseldorf, Düsseldorf, Germany.
Christos IliadisDepartment of Cardiology, Heart Center, University Hospital Cologne, Cologne, Germany.
Clemens MetzeDepartment of Cardiology, Heart Center, University Hospital Cologne, Cologne, Germany.
Patrick HornDepartment of Cardiology, Heart Center, University Hospital Düsseldorf, Düsseldorf, Germany.
Atsushi SugiuraDepartment of Medicine II, Heart Center Bonn, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Stephan BaldusDepartment of Cardiology, Heart Center, University Hospital Cologne, Cologne, Germany.
Malte KelmDepartment of Cardiology, Heart Center, University Hospital Düsseldorf, Düsseldorf, Germany.
Georg NickenigDepartment of Medicine II, Heart Center Bonn, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Roman PfisterDepartment of Cardiology, Heart Center, University Hospital Cologne, Cologne, Germany.
Ralf Westenfeld *Department of Cardiology, Heart Center, University Hospital Düsseldorf, Düsseldorf, Germany.
Marc Ulrich Becher *Department of Medicine II, Heart Center Bonn, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. ubecher@uni-bonn.de.ORCID http://orcid.org/0000-0002-6653-5046
University Hospital Bonn · DEDüsseldorf University Hospital · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatorenal dysfunction is a strong prognostic predictor in patients with heart failure. However, the prognostic impact of the hepatorenal dysfunction in patients undergoing transcatheter mitral valve repair (TMVR) has not been well studied.

methodsIn consecutive patients who underwent edge-to-edge TMVR at three German centers, the model for end-stage liver disease excluding international normalized ratio (MELD-XI) score was calculated as 5.11 × ln [serum total bilirubin (mg/dl)] + 11.76 × ln [serum creatinine (mg/dl)] + 9.44. Patients were stratified into high (> 11) or low (≤ 11) MELD-XI score of which an incidence of the composite outcome, consisting of all-cause mortality and heart failure hospitalization, within 2 years after TMVR was assessed.

resultsOf the 881 patients, the mean MELD-XI score was 11.0 ± 5.9, and 415 patients (47.1%) had high MELD-XI score. The MELD-XI score was correlated with male, effective regurgitant orifice area, and tricuspid regurgitation severity and inversely related to left ventricular ejection fraction. Patients with high MELD-XI score had a higher incidence of the composite outcome than those with low MELD-XI score (47.7% vs. 29.8%; p < 0.0001), and in multivariable analysis, the high MELD-XI score was an independent predictor of the composite outcome [adjusted hazard ratio (HR) 1.34; 95% confidence interval (CI) 1.02-1.77; p = 0.04). Additionally, the MELD-XI score as a continuous variable was also an independent predictor (adjusted HR 1.02; 95% CI 1.00-1.05; p = 0.048).

conclusionsThe MELD-XI score was associated with clinical outcomes within 2 years after TMVR and can be a useful risk-stratification tool in patients undergoing TMVR.

Indexed as

RegistriesAgedCardiac CatheterizationCardiac Surgical ProceduresEchocardiographyEnd Stage Liver DiseaseFemaleFollow-Up StudiesGermanyHumansIncidenceLiver Function TestsMaleMitral ValveMitral Valve InsufficiencyPostoperative ComplicationsHepatorenal dysfunctionMELD-XI scoreMitral regurgitationTranscatheter mitral valve repair

Identifiers

PMID34254179
PMCPMC8639570
OpenAlexW3177515186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.